Status:
COMPLETED
Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
Brief Summary
Post-marketing surveillance (PMS) to investigate the safety and efficacy of long-term daily use of Mirapex®-LA Tablets in patients with Parkinson's disease.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Patients with Parkinson's disease who have never been treated with Mirapex LA Tablets before enrolment will be included.
- Exclusion criteria:
- \- None
Exclusion
Key Trial Info
Start Date :
February 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
615 Patients enrolled
Trial Details
Trial ID
NCT01525641
Start Date
February 1 2012
End Date
June 1 2014
Last Update
August 14 2015
Active Locations (118)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 28
Abiko,Chiba, Japan
2
Boehringer Ingelheim Investigational Site 86
Akashi,Hyogo, Japan
3
Boehringer Ingelheim Investigational Site 13
Akita,Akita, Japan
4
Boehringer Ingelheim Investigational Site 9
Aomori,Aomori, Japan